Amlitelimab
- Generic Name
- Amlitelimab
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
- Conditions
- Dermatitis Atopic
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT06686628
- Locations
- 🇩🇪
Investigational Site Number : 2760001, Berlin, Germany
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
- Conditions
- Coeliac DiseaseCeliac Disease
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 204
- Registration Number
- NCT06557772
- Locations
- 🇦🇷
Investigational Site Number : 0320012, Buenos Aires, Argentina
🇹🇷Investigational Site Number : 7920003, Gaziantep, Turkey
🇺🇸FOMAT Medical Research - inSite Digestive Health Care - Arcadia- Site Number : 8400052, Arcadia, California, United States
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 166
- Registration Number
- NCT06444451
- Locations
- 🇯🇵
Investigational Site Number : 3920003, Ebina-shi, Kanagawa, Japan
🇯🇵Investigational Site Number : 3920001, Yokohama, Japan
🇯🇵Investigational Site Number : 3920002, Kamiamakusa, Kumamoto, Japan
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 961
- Registration Number
- NCT06407934
- Locations
- 🇨🇳
Investigational Site Number : 1560041, Shenyang, China
🇨🇳Investigational Site Number : 1560026, Shenyang, China
🇨🇳Investigational Site Number : 1560064, Shenzhen, China
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
- Conditions
- Dermatitis Atopic
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 249
- Registration Number
- NCT06241118
- Locations
- 🇨🇳
Investigational Site Number : 1560035, Ningbo, China
🇨🇳Investigational Site Number : 1560001, Shanghai, China
🇨🇳Investigational Site Number : 1560041, Shenyang, China
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
- Conditions
- Dermatitis Atopic
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 643
- Registration Number
- NCT06224348
- Locations
- 🇨🇳
Investigational Site Number : 1560047, Tianjin, China
🇨🇳Investigational Site Number : 1560049, Wuhan, China
🇨🇳Investigational Site Number : 1560003, Wuxi, China
Platform Clinical Study for Conquering Scleroderma
- Conditions
- Interstitial Lung Disease Due to Systemic DiseaseScleroderma
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Scleroderma Research Foundation, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT06195072
- Locations
- 🇺🇸
University of Alabama - Division of Pulmonary and Critical Care Medicine, Birmingham, Alabama, United States
🇺🇸Keck School of Medicine at USC Medical Center, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 547
- Registration Number
- NCT06181435
- Locations
- 🇨🇳
Investigational Site Number : 1560029, Hangzhou, China
🇨🇳Investigational Site Number : 1560007, Jinan, China
🇮🇹Investigational Site Number : 3800022, Vicenza, Italy
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 601
- Registration Number
- NCT06130566
- Locations
- 🇬🇷
Investigational Site Number : 3000002, Thessaloniki, Greece
🇬🇷Investigational Site Number : 3000003, Thessaloniki, Greece
🇮🇳Investigational Site Number : 3560001, Ahmedabad, India
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 90
- Registration Number
- NCT06118099
- Locations
- 🇺🇸
Medical Dermatology Specialists Site Number : 8400002, Phoenix, Arizona, United States
🇺🇸Center for Dermatology Clinical Research Site Number : 8400010, Fremont, California, United States
🇺🇸Corazon USA, LLC (DBA Life Clinical Trials) Site Number : 8400011, Margate, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.